A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 174 participants.
Also called NCT02111096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose basic science
- Phase
- Phase 2
- Enrolled
- 174 participants
- Sponsor
- Registry
-
NCT02111096 -
2013-004275-12
-
- Other papers using this trial's data
- Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Greece, Puerto Rico, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT02111096. Randomized; triple masking; primary purpose basic science. Start 2014-04 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2018-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LY2409021
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylurea
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02111096- Content hash
9a87965fad5f7b36b6aaafabc89f25665e6a47dc9f37208c693c9852490c43f7